Peptides for fighting ovarian cancer developed

August 8, 2011

A team of German and Italian EU-funded scientists has designed peptides that can target the protein-protein interface of an enzyme that plays a key part in the DNA synthesis crucial for cancer growth.

With a boost of EUR 1,902,150 of funding as part of the 'Small to interfere with Thymidylate synthase dimer formation as new tools for development of against ovarian carcinoma' (LIGHTS) project under the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6), the researchers developed peptides that act by a novel inhibitory mechanism and curb in drug resistant .

Writing in the journal PNAS, the scientists hope their research will go a long way to helping the some 200,000 women who are diagnosed annually worldwide with ovarian cancer.

In developed countries ovarian cancer is the fifth leading cause of cancer-related deaths in women. Unfortunately, there is a high rate of mortality among ovarian cancer sufferers due to frequent late diagnosis and the rapid rate of . Although several clinically important anti-cancer drugs that are widely used in chemotherapy inhibit the enzyme thymidylate synthase, which plays a key role in , these drugs are also associated with drug resistance. Thus new compounds with different inhibitory mechanisms are required to combat resistance.

According to the Italian and German scientists the answer is 'octapeptides', peptides that specifically target the protein-protein interface of thymidylate synthase, which is composed of two identical polypeptide chains. The peptides stabilise the inactive form of the enzyme, show a novel mechanism of inhibition for homodimeric enzymes and inhibit cell growth in drug sensitive and resistant cancer cell lines.

The researchers have discovered several peptides that inhibit thymidylate synthase by modulating protein-protein interactions. As one of the study's authors Maria Paola Costi from the University of Modena and Reggio Emilia in Italy explains: 'These peptides have sequences from the protein-protein interface of the enzyme and inhibit it by binding to a previously unknown allosteric binding site - that is, a site other than the protein's active site - at the protein-protein interface.'

The team used both experimental and computational approaches to show that their inhibitory mechanism involving stabilisation of an inactive form of the catalytic protein differs from those of protein-protein interface inhibitors reported to date.

Unlike the existing drugs targeting thymidylate synthase, these peptides inhibit intra-cellular thymidylate synthase and cell growth without leading to increased levels of thymidylate synthase protein when administered to cells. 'This observation indicates the potential value of these in overcoming drug resistance problems, although the cellular effects remain to be fully explored,' says another author on the study, Rebecca Wade from the Heidelberg Institute for Theoretical Studies.

The research was led by the University of Modena and Reggio Emilia, Italy and the Heidelberg Institute for Theoretical Studies in Germany. The other organisations involved were the Italian Universities of Siena, Milan and Ferrara.

The overall goal of the LIGHTS project, which ran from 2006 to 2010, was to directly halt tumour progression and the development of drug resistance upon treatment with platinum-derived drugs by inhibiting the protein regulatory function of monomeric TS through small molecule cellular perturbation. The consortium was made-up of both research institutions and small and medium-sized enterprises (SMEs) from France, Germany, Italy, the United Kingdom and the United States.

More information: Cardinal, D., et al. (2011) Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. PNAS. DOI: 10.1073/pnas.1104829108

Related Stories

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.